LYMPHOGENiX Overview
- Year Founded
-
2024
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$321K
- Investors
-
4
LYMPHOGENiX General Information
Description
Operator of a lymphatic vessel regeneration research company intended to help patients improve their vitality and treatment. The company leverages proprietary technology to revitalize lymphatic function and promote regeneration of various medical conditions to treat heart failure, and pulmonary fibrosis with substantial potential to tackle skin aging, obesity, Alzheimer's disease, and infertility.
Contact Information
Website
www.lymphogenix.comCorporate Office
- 71-75 Shelton Street
- Covent Garden
- London WC2H 9JQ
- England, United Kingdom
Corporate Office
- 71-75 Shelton Street
- Covent Garden
- London WC2H 9JQ
- England, United Kingdom
LYMPHOGENiX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 19-Nov-2024 | $321K | Completed | Startup |
LYMPHOGENiX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
LYMPHOGENiX Patents
LYMPHOGENiX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022344667-A1 | Fibroblast-containing pharmaceutical composition for treating kidney disease | Pending | 08-Sep-2021 | ||
| EP-4349349-A1 | Fibroblast-containing pharmaceutical composition for treating kidney disease | Inactive | 08-Sep-2021 | ||
| EP-4349349-A4 | Fibroblast-containing pharmaceutical composition for treating kidney disease | Inactive | 08-Sep-2021 | ||
| US-20240316113-A1 | Fibroblast-containing pharmaceutical composition for treating kidney disease | Pending | 08-Sep-2021 | ||
| AU-2022231584-A1 | Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same | Pending | 04-Mar-2021 | A61K35/33 |
LYMPHOGENiX Signals
LYMPHOGENiX Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AndJ Holdings | Venture Capital | Minority | ||
| Glocalink | Venture Capital | Minority | ||
| Keio Innovation Initiative | Venture Capital | Minority | ||
| S-Quatre | Corporation | Minority |
LYMPHOGENiX FAQs
-
When was LYMPHOGENiX founded?
LYMPHOGENiX was founded in 2024.
-
Where is LYMPHOGENiX headquartered?
LYMPHOGENiX is headquartered in London, United Kingdom.
-
What is the size of LYMPHOGENiX?
LYMPHOGENiX has 3 total employees.
-
What industry is LYMPHOGENiX in?
LYMPHOGENiX’s primary industry is Biotechnology.
-
Is LYMPHOGENiX a private or public company?
LYMPHOGENiX is a Private company.
-
What is the current valuation of LYMPHOGENiX?
The current valuation of LYMPHOGENiX is .
-
What is LYMPHOGENiX’s current revenue?
The current revenue for LYMPHOGENiX is .
-
How much funding has LYMPHOGENiX raised over time?
LYMPHOGENiX has raised $321K.
-
Who are LYMPHOGENiX’s investors?
AndJ Holdings, Glocalink, Keio Innovation Initiative, and S-Quatre have invested in LYMPHOGENiX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process